Table 1.

Clinical trials for Reducing Glucocorticoids in Symptomatic Sarcoidosis

Drug studied	Number of patients Drug/Placebo	Background therapy	Change in FVC % predicted	Prednisone Taper	Change in Quality of Life	Comments
Methotrexate 27	9 Methotrexate; 6 Placebo	Prednisone	11%	Significant prednisone tapering	Not reported	No significant change in FVC absolute value. Excluded from analysis 7 patients treated started on methotrexate and withdrew from study
Fluticasone 28	10 Fluticasone; 12 Placebo	Prednisone	No significant change	No significant difference	No difference in SF-36	Less cough reported with fluticasone. No objective measurement reported.
Pentoxifylline 29	12 Pentoxifylline; 13 Placebo	Prednisone	No significant difference	yes	Not reported	Significant steroid sparing only at 8 and 10 months; Significantly less flares with prednisone tapering; Did not report FVC results
Golimumab 30	42 Golimumab; 44 Placebo	Prednisone plus other agents	-0.87%	no change in prednisone	No significant changes	Same placebo patients for golimumab and ustekinumab trial
Ustekinumab 30	46 Ustekinumab; 44 Placebo	Prednisone plus other agents	-2.17%	no change in prednisone	No significant changes	Same placebo patients for golimumab and ustekinumab trial
Efzofitimod 31	27 Efzofitimod; 12 Placebo;	Prednisone plus other agents	2.81 % at 3 mg/kg; 3.30 at 5 mg/kg	Dose response effect seen for prednisone tapering	Statistically significant (p value <0.05) improvement in KSQ Lung, KSQ GH and FAS	Underpowered to demonstrate significant changes in FVC